For primary hyperlipidemia. ANDA 209946, held by Zhejiang Jingxin. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 209946 (Colesevelam Hydrochloride), held by Zhejiang Jingxin, was first approved by FDA on Jul 15, 2020, with 1 approved supplement and 0 published complete response letters.
Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification. improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis. Not studied in Fredrickson Type I, III, IV, and V dyslipidemias 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride625MG · tablet;oral | Colesevelam Hydrochloride | Rx |
| Jul 26, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 15, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters